Skip to main content
Terug
COGT logo

Cogent Biosciences, Inc.

Datakwaliteit: 100%
COGT
NASDAQ Healthcare Biotechnology
€ 34,96
▼ € 0,45 (-1,27%)
Marktkapitalisatie: 5,67B
Dagbereik
€ 34,05 € 35,14
52-Weeksbereik
€ 3,72 € 43,73
Volume
1.849.362
50D / 200D Gem.
€ 37,17 / € 23,42
Vorige Slotkoers
€ 35,41

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -17,3 0,3
P/B 8,9 2,9
ROE % -73,7 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,4 0,2

Koersdoel Analisten

Hold
€ 48,13 +37.7%
Low: € 35,00 High: € 60,00
Forward WPA
-€ 2,14
Omzet Sch.
18 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,76
€ 0,57 – € 12,01
1,7 B 6
FY2029 € 3,07
€ 0,37 – € 7,75
1,3 B 6
FY2028 € 1,05
€ 0,23 – € 2,35
760 M 8

Belangrijkste Punten

Debt/Equity of 0,40 — conservative balance sheet
Negative free cash flow of -266,00M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-73,70%
ROIC-28,11%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,40
Current Ratio14,23
Interest Coverage-108,87

Waardering

P/E Ratio
-17,25
P/B Ratio8,92
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -328,94M
ROE -73,70% ROA -35,08%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -266,00M
ROIC -28,11% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,40 Current Ratio 14,23
Interest Coverage -108,87 Dividend Yield 0,00%
Valuation
P/E Ratio -17,25 P/B Ratio 8,92
P/S Ratio N/A PEG Ratio -2,00
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 5,67B Enterprise Value 5,62B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -328,94M -255,86M -192,41M -140,24M -72,27M
EPS (Diluted) -2,55 -2,46 -2,42 -2,26 -1,85
Gross Profit -4,62M 0,0 0,0 0,0 0,0
Operating Income -333,36M -275,94M -208,13M -147,84M -75,55M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 937,61M 327,90M 313,44M 300,81M 232,09M
Total Liabilities 301,24M 71,61M 55,64M 45,08M 17,91M
Shareholders' Equity 636,37M 256,29M 257,80M 255,74M 214,18M
Total Debt 253,15M 17,47M 18,85M 19,65M 3,16M
Cash & Equivalents 312,01M 98,17M 53,23M 139,89M 219,68M
Current Assets 910,36M 296,47M 270,77M 264,97M 222,63M
Current Liabilities 63,95M 55,71M 38,17M 26,85M 17,08M